Engineered immune cells take aim at Hard-to-Treat lupus

NCT ID NCT07328581

Not yet recruiting Disease control Sponsor: iCell Gene Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-phase trial tests a new type of cell therapy called BCMA-CD19-IL-15/IL15sushi compound CAR T cells in 20 people with severe lupus that hasn't improved with standard treatments. The therapy aims to reset the immune system by targeting and eliminating faulty immune cells. Researchers will monitor safety and check if the treatment can reduce lupus disease activity and autoantibodies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BCMA-CD19-IL-15/IL15sushi compound CAR T cells (a type of immune cell therapy)
What this could lead to: If successful, this could offer a new treatment option for people with severe lupus that hasn't responded to standard therapies, potentially reducing disease activity and need for medications.
What could go wrong: This is an early-phase trial with only 20 participants, so results may not apply to everyone. CAR T therapy can cause serious side effects like cytokine release syndrome and infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUPUS NEPHRITIS (LN) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune disease disease lupus nephritis systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUPUS NEPHRITIS (LN) SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

More trials for these conditions

Other studies related to the condition(s) this trial covers.